tiprankstipranks
Trending News
More News >

Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, expanded the marketing authorization for Dupixent in the European Union, or EU, to treat eosinophilic esophagitis, or EoE, in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat EoE in Europe and the U.S.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on REGN:

Disclaimer & DisclosureReport an Issue